Redcare Pharmacy Past Earnings Performance
Past criteria checks 0/6
Redcare Pharmacy's earnings have been declining at an average annual rate of -0.7%, while the Consumer Retailing industry saw earnings growing at 8.7% annually. Revenues have been growing at an average rate of 22.4% per year.
Key information
-0.7%
Earnings growth rate
5.3%
EPS growth rate
Consumer Retailing Industry Growth | 10.5% |
Revenue growth rate | 22.4% |
Return on equity | -5.0% |
Net Margin | -1.1% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Here's Why Redcare Pharmacy (ETR:RDC) Can Afford Some Debt
Nov 11Is There Now An Opportunity In Redcare Pharmacy NV (ETR:RDC)?
Apr 21Are Investors Undervaluing Redcare Pharmacy NV (ETR:RDC) By 26%?
Apr 07Investors Interested In Redcare Pharmacy NV's (ETR:RDC) Revenues
Mar 25Redcare Pharmacy (ETR:RDC) Is Carrying A Fair Bit Of Debt
Feb 13Why Investors Shouldn't Be Surprised By Redcare Pharmacy NV's (ETR:RDC) P/S
Dec 24Is There An Opportunity With Redcare Pharmacy NV's (ETR:RDC) 48% Undervaluation?
Dec 06Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?
Sep 07Why Redcare Pharmacy NV (ETR:RDC) Could Be Worth Watching
Aug 02Why We're Not Concerned About Redcare Pharmacy NV's (ETR:RDC) Share Price
Jul 17Broker Revenue Forecasts For Shop Apotheke Europe N.V. (ETR:SAE) Are Surging Higher
May 28Here's Why Shop Apotheke Europe (ETR:SAE) Can Afford Some Debt
May 11We Think Shop Apotheke Europe (ETR:SAE) Has A Fair Chunk Of Debt
Jan 10Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?
Sep 25Is Shop Apotheke Europe (ETR:SAE) Weighed On By Its Debt Load?
Jun 08Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?
Feb 28Here's Why Shop Apotheke Europe (ETR:SAE) Has A Meaningful Debt Burden
Aug 01Shop Apotheke Europe N.V.'s (ETR:SAE) About To Shift From Loss To Profit
May 11Revenue & Expenses Breakdown
How Redcare Pharmacy makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 2,227 | -25 | 532 | 0 |
30 Jun 24 | 2,128 | -9 | 501 | 0 |
31 Mar 24 | 1,987 | -10 | 473 | 0 |
31 Dec 23 | 1,799 | -12 | 444 | 0 |
30 Sep 23 | 1,595 | -16 | 419 | 0 |
30 Jun 23 | 1,404 | -45 | 392 | 0 |
31 Mar 23 | 1,272 | -65 | 393 | 0 |
31 Dec 22 | 1,204 | -78 | 379 | 0 |
30 Sep 22 | 1,165 | -110 | 368 | 0 |
30 Jun 22 | 1,118 | -105 | 359 | 0 |
31 Mar 22 | 1,081 | -91 | 320 | 0 |
31 Dec 21 | 1,060 | -74 | 299 | 0 |
30 Sep 21 | 1,037 | -39 | 277 | 0 |
30 Jun 21 | 1,038 | -29 | 256 | 0 |
31 Mar 21 | 1,020 | -18 | 238 | 0 |
31 Dec 20 | 968 | -17 | 214 | 0 |
30 Sep 20 | 895 | -15 | 194 | 0 |
30 Jun 20 | 827 | -20 | 182 | 0 |
31 Mar 20 | 758 | -27 | 169 | 0 |
31 Dec 19 | 701 | -36 | 166 | 0 |
30 Sep 19 | 660 | -41 | 162 | 0 |
30 Jun 19 | 621 | -40 | 151 | 0 |
31 Mar 19 | 584 | -40 | 142 | 0 |
31 Dec 18 | 540 | -34 | 127 | 0 |
30 Sep 18 | 481 | -31 | 116 | 0 |
30 Jun 18 | 415 | -28 | 104 | 0 |
31 Mar 18 | 351 | -24 | 92 | 0 |
31 Dec 17 | 284 | -21 | 80 | 0 |
30 Sep 17 | 244 | -22 | 70 | 0 |
30 Jun 17 | 222 | -20 | 63 | 0 |
31 Mar 17 | 200 | -20 | 57 | 0 |
31 Dec 16 | 177 | -18 | 50 | 0 |
30 Sep 16 | 159 | -13 | 45 | 0 |
30 Jun 16 | 147 | -13 | 43 | 0 |
31 Mar 16 | 136 | -12 | 40 | 0 |
31 Dec 15 | 126 | -11 | 36 | 0 |
31 Dec 14 | 85 | -5 | 23 | 0 |
31 Dec 13 | 55 | -3 | 15 | 0 |
Quality Earnings: RDC is currently unprofitable.
Growing Profit Margin: RDC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RDC is unprofitable, and losses have increased over the past 5 years at a rate of 0.7% per year.
Accelerating Growth: Unable to compare RDC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RDC is unprofitable, making it difficult to compare its past year earnings growth to the Consumer Retailing industry (3.2%).
Return on Equity
High ROE: RDC has a negative Return on Equity (-4.96%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 12:15 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Redcare Pharmacy NV is covered by 26 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Volker Bosse | Baader Helvea Equity Research |
Gerhard Schwarz | Baader Helvea Equity Research |
Alvira Rao | Barclays |